公开(公告)号：US20230042358A1

公开(公告)日：2023-02-09

申请号：US17413469

申请日：2019-12-11

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Jun CHIBA ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC分类号： C07D455/02 ,  A61P25/26 ,  C07D471/04 ,  C07D217/24 ,  C07D239/90 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D498/04 ,  C07D417/06 ,  C07D401/06

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220017514A1

公开(公告)日：2022-01-20

申请号：US17413473

申请日：2019-12-11

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC分类号： C07D471/04 ,  C07D231/56 ,  C07D277/64 ,  C07D215/38 ,  C07D401/14

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220388995A1

公开(公告)日：2022-12-08

申请号：US17550173

申请日：2021-12-14

申请人： Takeda Pharmaceutical Company Limited

发明人： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC分类号： C07D409/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20200231579A1

公开(公告)日：2020-07-23

申请号：US16634402

申请日：2018-07-26

申请人： Takeda Pharmaceutical Company Limited

发明人： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC分类号： C07D409/12 ,  C07D231/56 ,  C07D235/06 ,  C07D401/12 ,  C07D249/18 ,  A61K9/48 ,  A61K9/20 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28

摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.